News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Global Phase-3 study initiation expected in the second half of 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Subscribe To Our Newsletter & Stay Updated
